Virios Therapeutics reports Q1 2023 net loss of $1.5M; FDA amenable to IMC-1 Phase 3 proposal

Dogwood Therapeutics, Inc.

2023-Q1 EPS reported -$0.08

Net loss $1.5M ($0.08 per share) vs $4.0M ($0.48) in Q1 2022; R&D expenses fell to $0.5M from $2.8M.
Cash $5.3M as of March 31, 2023; company expects runway into Q2 2024, but IMC-1 trials need additional funding.
FDA amenable to Phase 3 program for IMC-1 (famciclovir/celecoxib) for fibromyalgia, pending review of chronic toxicology reports submitted in May 2023.
Top-line results from exploratory Long-COVID study (valacyclovir/celecoxib) expected in June 2023.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Dogwood Therapeutics, Inc. reported the first quarter ended March 31, 2023 results: net income Net loss for the first quarter of 2023 was $1.5 million, or $0.08 basic and diluted net loss per share, EPS $0.08 basic and diluted net loss per share.

Period: the first quarter ended March 31, 2023
Net income: Net loss for the first quarter of 2023 was $1.5 million, or $0.08 basic and diluted net loss per share
EPS: $0.08 basic and diluted net loss per share
Result: reported results

Exact text from the filing

Net loss for the first quarter of 2023 was $1.5 million, or $0.08 basic and diluted net loss per share

View on SEC.gov

Browse all earnings releases →

Dogwood Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001558370-23-009260

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.